Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for Hard-to-Treat myeloma: experimental drug tested in chinese patients

NCT ID NCT06934044

First seen Oct 31, 2025 · Last updated Jun 18, 2026 · Updated 27 times

Summary

This early-stage study tests an experimental drug called cevostamab in about 20 Chinese adults whose multiple myeloma has returned or stopped responding to standard treatments. The main goals are to check the drug's safety, how the body processes it, and whether it can shrink tumors. Participants must be in fairly good health and have a life expectancy of at least 12 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Sun yat-sen University Cancer Center

    RECRUITING

    Guangzhou, Guangdong, 510555, China

  • The First Affiliated Hospital of Nanchang University

    RECRUITING

    Nanchang, China

  • The First Affiliated Hospital of Wenzhou Medical University

    RECRUITING

    Wenzhou, 325035, China

  • Tianjin Institute of Hematology & Blood Diseases Hospital

    RECRUITING

    Tianjin, Tianjin Municipality, 301636, China

  • Tongji Hospital Tongji Medical College Huazhong University of Science and Technology

    RECRUITING

    Wuhan, 430030, China

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.